A Prospective, Open, Non-interventional Study to Assess the Tolerability and the Safety Profile of SCIT Therapy With Acarovac Hausstaubmilbe in Patients With HDM-induced Rhinoconjunctivitis With or Without Allergic Asthma
Phase of Trial: Phase IV
Latest Information Update: 25 Apr 2019
Price : $35 *
At a glance
- Drugs House dust mite allergy immunotherapy Allergy Therapeutics (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Adverse reactions
- 23 Apr 2019 Status changed from recruiting to completed.
- 03 May 2018 Planned End Date changed from 30 Sep 2017 to 31 Dec 2018.
- 03 May 2018 Planned primary completion date changed from 30 Sep 2017 to 31 Dec 2018.